(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Rocket Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RCKT's revenue for 2025 to be $1,491,231,497, with the lowest RCKT revenue forecast at $1,491,231,497, and the highest RCKT revenue forecast at $1,491,231,497. On average, 3 Wall Street analysts forecast RCKT's revenue for 2026 to be $9,653,835,627, with the lowest RCKT revenue forecast at $400,323,361, and the highest RCKT revenue forecast at $28,055,114,364.
In 2027, RCKT is forecast to generate $2,707,416,027 in revenue, with the lowest revenue forecast at $2,702,128,738 and the highest revenue forecast at $2,712,703,317.